Application of CDK4/6 inhibitors in the treatment of hormone receptorpositive breast cancer%0 Journal Article %D 2019 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2019.10.010 %P 617-619 %V 46 %N 10 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10714.shtml} %8 2019-10-08 %X
With roles of blocking cell proliferation, cyclindependent protein kinase (CDK) 4/6 inhibitors are effective and safe complementary therapies for hormone receptorpositive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into earlystage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive.